#842: The Story Behind EpiPen, The Rise of Food Allergies, and What Doctors Got Wrong - The Tim Ferriss Show Recap
Podcast: The Tim Ferriss Show
Published: 2025-12-30
Duration: 59 minutes
Guests: Thomas Goetz, Alexander Haju, Gideon Lack
Summary
The episode delves into the history and economics of the EpiPen, exploring the rise of food allergies and how past medical recommendations may have contributed to this trend. It examines the scientific and commercial landscape around allergy prevention and treatment.
What Happened
The episode features the first installment of a new podcast, 'Drug Story', hosted by Thomas Goetz. It focuses on the EpiPen and the rise of food allergies, a topic of personal interest to Tim Ferriss, who carries an EpiPen himself. The episode begins by discussing the alarming increase in food allergies over the past 50 years, affecting approximately 10% of adults and children in the U.S. by 2024. The hygiene hypothesis suggests that increased cleanliness may have weakened immune systems, contributing to this rise.
In a controversial twist, the episode explores how a 2000 recommendation by the American Academy of Pediatrics to delay the introduction of allergenic foods to children was later found to be unfounded. This advice might have unintentionally led to an increase in food allergies. Research by Dr. Gideon Lack in Israel showed that early exposure to peanut-based snacks significantly reduced peanut allergies, contradicting prior guidelines.
The history of the EpiPen is explored, tracing its origins to a military device called the combo pen, invented by Sheldon Kaplan. The EpiPen, which delivers the drug epinephrine, was first highlighted in the New York Times in 1990 after a tragic incident involving a peanut allergy. The device became a commercial success, with revenue reaching around $200 million annually between 2003 and 2007.
Mylan Pharmaceuticals acquired the EpiPen in 2007 and subsequently raised its price sharply, from about $109 to over $300 per two-pack by 2016. This price hike was accompanied by lobbying efforts to make EpiPens mandatory in schools, which further boosted sales. By 2023, the EpiPen and its generic version generated nearly $2 billion in revenue.
The episode also covers the LEAP study, published in 2015, which demonstrated the benefits of early exposure to peanuts in preventing allergies. The study found that allergy rates dropped from 14% to 1.9% with early exposure, leading to new U.S. guidelines in 2017 recommending this approach.
Despite these new guidelines, food allergies continue to rise among children and adults. The episode ends by discussing the FDA's approval of Palforzia in 2020, a treatment for peanut allergies that uses allergen immunotherapy, indicating ongoing efforts to address this public health issue.
Key Insights
- Food allergies have increased significantly over the past 50 years, with approximately 10% of adults and children in the U.S. expected to be affected by 2024. The hygiene hypothesis suggests that increased cleanliness has weakened immune systems, contributing to this rise.
- A 2000 recommendation by the American Academy of Pediatrics to delay the introduction of allergenic foods was later found to be unfounded. Research showed that early exposure to peanut-based snacks significantly reduced peanut allergies, leading to updated guidelines in 2017.
- The EpiPen, originally derived from a military device called the combo pen, became a commercial success with revenues reaching around $200 million annually between 2003 and 2007. Mylan Pharmaceuticals acquired it in 2007 and raised its price sharply, resulting in nearly $2 billion in revenue by 2023.
- The LEAP study published in 2015 demonstrated that early exposure to peanuts reduced allergy rates from 14% to 1.9%. Despite new guidelines recommending early exposure, food allergies continue to rise, prompting ongoing efforts to address the issue, including the FDA's approval of Palforzia in 2020.